166 related articles for article (PubMed ID: 30081250)
1. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.
Mohan T; Kim J; Berman Z; Wang S; Compans RW; Wang BZ
J Control Release; 2016 Jul; 233():208-19. PubMed ID: 27178810
[TBL] [Abstract][Full Text] [Related]
3. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses.
Mohan T; Berman Z; Luo Y; Wang C; Wang S; Compans RW; Wang BZ
Sci Rep; 2017 Jan; 7():40226. PubMed ID: 28067290
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
5. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.
Patel JM; Kim MC; Vartabedian VF; Lee YN; He S; Song JM; Choi HJ; Yamanaka S; Amaram N; Lukacher A; Montemagno CD; Compans RW; Kang SM; Selvaraj P
Nanomedicine; 2015 Jul; 11(5):1097-107. PubMed ID: 25752855
[TBL] [Abstract][Full Text] [Related]
6. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
[TBL] [Abstract][Full Text] [Related]
7. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
[TBL] [Abstract][Full Text] [Related]
10. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
11. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice.
Park BR; Bommireddy R; Chung DH; Kim KH; Subbiah J; Jung YJ; Bhatnagar N; Pack CD; Ramachandiran S; Reddy SJC; Selvaraj P; Kang SM
Immun Ageing; 2023 May; 20(1):20. PubMed ID: 37170231
[TBL] [Abstract][Full Text] [Related]
15. Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.
Kang H; Qi Y; Wang H; Zheng X; Gao Y; Li N; Yang S; Xia X
Viruses; 2015 Mar; 7(3):1134-52. PubMed ID: 25768031
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.
Cheng LF; Wang F; Zhang L; Yu L; Ye W; Liu ZY; Ying QK; Wu XA; Xu ZK; Zhang FL
Front Cell Infect Microbiol; 2016; 6():185. PubMed ID: 28066721
[TBL] [Abstract][Full Text] [Related]
18. Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.
Cox F; Saeland E; Baart M; Koldijk M; Tolboom J; Dekking L; Koudstaal W; Lövgren Bengtsson K; Goudsmit J; Radošević K
Virol J; 2015 Dec; 12():210. PubMed ID: 26643820
[TBL] [Abstract][Full Text] [Related]
19. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.
Schwartzman LM; Cathcart AL; Pujanauski LM; Qi L; Kash JC; Taubenberger JK
mBio; 2015 Jul; 6(4):e01044. PubMed ID: 26199334
[TBL] [Abstract][Full Text] [Related]
20. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice.
Schneider-Ohrum K; Giles BM; Weirback HK; Williams BL; DeAlmeida DR; Ross TM
Vaccine; 2011 Nov; 29(48):9081-92. PubMed ID: 21963872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
